Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02389764 | Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC) | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT00759642 | Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy | terminated | Phase 2 | 33 | University of Kansas Medical CenterOTHER | 1 | Jul 1, 2019 | clinicaltrials |
| NCT01159067 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload |
| terminated |
| Phase 2 |
| 1 |
| City of Hope Medical CenterOTHER |
| 1 |
| Jun 18, 2019 |
| clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00784524 | Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca | terminated | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT02012608 | Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy | terminated | Phase 2 | 14 | University of ArkansasOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT02674204 | STOP Heart Disease in Breast Cancer Survivors Trial(STOP) | terminated | Phase 2 | 2 | Cedars-Sinai Medical CenterOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02658084 | Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 2 | University of MiamiOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT00462865 | Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse | terminated | Phase 2 | 18 | Brown UniversityOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT00080626 | Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer | terminated | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00130507 | Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab | terminated | Phase 2 | 14 | Spanish Breast Cancer Research GroupOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00434941 | Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours | terminated | Phase 2 | 1 | Spanish Breast Cancer Research GroupOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT00096369 | Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer | terminated | Phase 2 | 130 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT01185509 | Trastuzumab and Vinorelbine in Advanced Breast Cancer | terminated | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT02374099 | Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | terminated | Phase 2 | 97 | CelgeneINDUSTRY | 6 | Dec 14, 2018 | clinicaltrials |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | terminated | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01864798 | A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer(D-Beyond) | terminated | Phase 2 | 27 | Jules Bordet InstituteOTHER | 2 | Nov 27, 2018 | clinicaltrials |
| NCT03070002 | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells | terminated | Phase 2 | 1 | Northwestern UniversityOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02347163 | Pre-operative Zoledronate in Triple Negative Breast Cancer | terminated | Phase 2 | 22 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00214149 | Multi-catheter High Dose Rate (HDR) Breast Brachytherapy | terminated | Phase 2 | 127 | University of Wisconsin, MadisonOTHER | 1 | Nov 5, 2018 | clinicaltrials |
| NCT02375048 | Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI | terminated | Phase 2 | 179 | Istituto Clinico HumanitasOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT02297230 | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | terminated | Phase 1 / Phase 2 | 44 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment(VICTOR3) | terminated | Phase 2 | 4 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Oct 5, 2018 | clinicaltrials |
| NCT01690325 | Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | terminated | Phase 2 | 21 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00088972 | S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women | terminated | Phase 2 | 8 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00225758 | Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | terminated | Phase 2 | 27 | Gary SchwartzOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT00852332 | Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer | terminated | Phase 2 | 42 | Centre Jean PerrinOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00169104 | Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | terminated | Phase 2 / Phase 3 | 23 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | Jul 20, 2018 | clinicaltrials |
| NCT01388777 | Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT00088829 | Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer | terminated | Phase 2 | 22 | Georgetown UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01009983 | Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer | terminated | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2018 | clinicaltrials |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | terminated | Phase 1 / Phase 2 | 81 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03407430 | Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain | terminated | Phase 2 | 11 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01776008 | Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 8, 2018 | clinicaltrials |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer(STEFNE) | terminated | Phase 1 / Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT00824538 | Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow | terminated | Phase 2 | 13 | University of California, San FranciscoOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT01010854 | Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer(VPA-FEC100) | terminated | Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02596867 | Neoadjuvant Propanolol in Breast Cancer(NPBC) | terminated | Phase 2 | 2 | Texas Tech University Health Sciences Center, El PasoOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00722072 | Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy | terminated | Phase 2 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT01698281 | Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer | terminated | Phase 2 | 7 | AEterna ZentarisINDUSTRY | 2 | Feb 22, 2018 | clinicaltrials |
| NCT01887288 | Capecitabine With Digoxin for Metastatic Breast Cancer | terminated | Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT02345772 | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy(Neohttp) | terminated | Phase 1 / Phase 2 | 4 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00632541 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | terminated | Phase 2 | 18 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 14, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jul 17, 2019source: clinicaltrials